| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neoplasms | 72 | 2026 | 857 | 15.210 |
Why?
|
| Palliative Care | 27 | 2026 | 84 | 6.320 |
Why?
|
| Pancreatic Neoplasms | 20 | 2025 | 548 | 5.370 |
Why?
|
| Gastrointestinal Neoplasms | 15 | 2025 | 41 | 5.190 |
Why?
|
| Quality of Life | 36 | 2026 | 504 | 4.960 |
Why?
|
| Patient Reported Outcome Measures | 16 | 2025 | 66 | 4.720 |
Why?
|
| Medical Oncology | 9 | 2025 | 97 | 4.280 |
Why?
|
| Hospitalization | 18 | 2023 | 199 | 4.070 |
Why?
|
| Aged | 93 | 2026 | 5525 | 3.700 |
Why?
|
| Lung Neoplasms | 13 | 2022 | 357 | 3.320 |
Why?
|
| Humans | 154 | 2026 | 28585 | 3.150 |
Why?
|
| Cost of Illness | 12 | 2025 | 54 | 2.960 |
Why?
|
| Adenocarcinoma | 9 | 2025 | 300 | 2.920 |
Why?
|
| Terminal Care | 9 | 2022 | 43 | 2.520 |
Why?
|
| Male | 90 | 2026 | 13772 | 2.320 |
Why?
|
| Clinical Trials as Topic | 7 | 2026 | 216 | 2.280 |
Why?
|
| Middle Aged | 68 | 2026 | 7310 | 2.280 |
Why?
|
| Aged, 80 and over | 40 | 2026 | 2045 | 2.170 |
Why?
|
| Female | 93 | 2026 | 15472 | 2.120 |
Why?
|
| Depression | 13 | 2021 | 222 | 2.020 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 6 | 2022 | 105 | 1.980 |
Why?
|
| Patient Acceptance of Health Care | 6 | 2025 | 100 | 1.820 |
Why?
|
| Patient Participation | 7 | 2021 | 56 | 1.780 |
Why?
|
| Caregivers | 10 | 2025 | 118 | 1.730 |
Why?
|
| Antineoplastic Agents | 9 | 2024 | 681 | 1.670 |
Why?
|
| Geriatric Assessment | 8 | 2026 | 91 | 1.660 |
Why?
|
| Carcinoma, Pancreatic Ductal | 7 | 2025 | 146 | 1.610 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 10 | 2026 | 414 | 1.590 |
Why?
|
| Adaptation, Psychological | 8 | 2025 | 122 | 1.540 |
Why?
|
| Health Care Costs | 5 | 2020 | 50 | 1.440 |
Why?
|
| Surveys and Questionnaires | 20 | 2025 | 994 | 1.370 |
Why?
|
| Sarcopenia | 3 | 2021 | 43 | 1.370 |
Why?
|
| Adult | 42 | 2026 | 7922 | 1.350 |
Why?
|
| Patient Readmission | 3 | 2022 | 107 | 1.280 |
Why?
|
| Prognosis | 21 | 2025 | 807 | 1.260 |
Why?
|
| Health Services Accessibility | 5 | 2021 | 116 | 1.230 |
Why?
|
| Patient Selection | 4 | 2021 | 149 | 1.210 |
Why?
|
| Neoadjuvant Therapy | 6 | 2024 | 74 | 1.180 |
Why?
|
| Geriatrics | 2 | 2021 | 47 | 1.150 |
Why?
|
| Symptom Assessment | 4 | 2022 | 15 | 1.090 |
Why?
|
| Colorectal Neoplasms | 6 | 2021 | 141 | 1.060 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2024 | 163 | 1.000 |
Why?
|
| Cancer Survivors | 4 | 2021 | 61 | 0.980 |
Why?
|
| Esophageal Neoplasms | 2 | 2024 | 32 | 0.970 |
Why?
|
| Physician-Patient Relations | 4 | 2020 | 116 | 0.960 |
Why?
|
| Camptothecin | 2 | 2015 | 16 | 0.920 |
Why?
|
| Cross-Sectional Studies | 17 | 2025 | 988 | 0.910 |
Why?
|
| Artificial Intelligence | 1 | 2025 | 55 | 0.900 |
Why?
|
| Telemedicine | 5 | 2025 | 187 | 0.890 |
Why?
|
| Medicare Part D | 1 | 2024 | 5 | 0.880 |
Why?
|
| Survivors | 5 | 2021 | 40 | 0.880 |
Why?
|
| Prescription Drugs | 1 | 2024 | 15 | 0.870 |
Why?
|
| Lobbying | 1 | 2024 | 9 | 0.860 |
Why?
|
| Germ-Line Mutation | 1 | 2024 | 31 | 0.860 |
Why?
|
| Informed Consent | 2 | 2021 | 25 | 0.840 |
Why?
|
| Genetic Testing | 1 | 2024 | 68 | 0.840 |
Why?
|
| Pain Management | 3 | 2025 | 62 | 0.810 |
Why?
|
| United States | 15 | 2025 | 2201 | 0.800 |
Why?
|
| Medicare | 5 | 2020 | 126 | 0.800 |
Why?
|
| Affect | 4 | 2020 | 85 | 0.790 |
Why?
|
| Inpatients | 2 | 2022 | 60 | 0.780 |
Why?
|
| SEER Program | 7 | 2023 | 47 | 0.780 |
Why?
|
| Treatment Outcome | 8 | 2025 | 2402 | 0.770 |
Why?
|
| Body Composition | 3 | 2021 | 266 | 0.740 |
Why?
|
| Length of Stay | 6 | 2023 | 240 | 0.730 |
Why?
|
| Personal Satisfaction | 1 | 2022 | 31 | 0.720 |
Why?
|
| Analgesics, Opioid | 2 | 2025 | 117 | 0.720 |
Why?
|
| Healthcare Disparities | 3 | 2021 | 93 | 0.720 |
Why?
|
| Insurance Coverage | 5 | 2021 | 31 | 0.710 |
Why?
|
| Severity of Illness Index | 3 | 2019 | 461 | 0.710 |
Why?
|
| Anxiety | 9 | 2022 | 157 | 0.700 |
Why?
|
| Activities of Daily Living | 3 | 2025 | 106 | 0.690 |
Why?
|
| Hematology | 1 | 2021 | 25 | 0.690 |
Why?
|
| Head and Neck Neoplasms | 1 | 2022 | 92 | 0.680 |
Why?
|
| Muscle, Skeletal | 4 | 2021 | 638 | 0.680 |
Why?
|
| Health Expenditures | 7 | 2025 | 30 | 0.670 |
Why?
|
| Registries | 3 | 2021 | 393 | 0.660 |
Why?
|
| Hospice Care | 5 | 2021 | 16 | 0.660 |
Why?
|
| Electronics | 1 | 2020 | 4 | 0.650 |
Why?
|
| Monitoring, Physiologic | 1 | 2020 | 57 | 0.630 |
Why?
|
| Randomized Controlled Trials as Topic | 6 | 2025 | 389 | 0.620 |
Why?
|
| Income | 2 | 2019 | 38 | 0.620 |
Why?
|
| Financial Statements | 1 | 2019 | 2 | 0.610 |
Why?
|
| Financing, Personal | 1 | 2019 | 4 | 0.610 |
Why?
|
| Travel | 1 | 2019 | 12 | 0.610 |
Why?
|
| Monitoring, Ambulatory | 1 | 2019 | 26 | 0.600 |
Why?
|
| Lymphoma, Non-Hodgkin | 3 | 2026 | 27 | 0.590 |
Why?
|
| Early Detection of Cancer | 1 | 2020 | 132 | 0.590 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2023 | 44 | 0.590 |
Why?
|
| Self Report | 4 | 2022 | 121 | 0.590 |
Why?
|
| Emergency Service, Hospital | 1 | 2020 | 121 | 0.580 |
Why?
|
| Antidepressive Agents | 1 | 2018 | 29 | 0.570 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2018 | 10 | 0.570 |
Why?
|
| Age Factors | 7 | 2021 | 734 | 0.570 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2022 | 43 | 0.570 |
Why?
|
| Pilot Projects | 6 | 2025 | 458 | 0.560 |
Why?
|
| Breast Neoplasms | 6 | 2020 | 472 | 0.550 |
Why?
|
| Decision Making | 6 | 2025 | 177 | 0.550 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2018 | 69 | 0.540 |
Why?
|
| Patient Preference | 5 | 2025 | 33 | 0.530 |
Why?
|
| Multimorbidity | 1 | 2017 | 3 | 0.530 |
Why?
|
| Communication | 2 | 2019 | 179 | 0.530 |
Why?
|
| Drug Industry | 1 | 2016 | 14 | 0.520 |
Why?
|
| Retrospective Studies | 18 | 2026 | 2612 | 0.510 |
Why?
|
| Conflict of Interest | 1 | 2016 | 16 | 0.510 |
Why?
|
| Delivery of Health Care | 4 | 2024 | 118 | 0.510 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2016 | 5 | 0.510 |
Why?
|
| Pancreatectomy | 1 | 2017 | 58 | 0.510 |
Why?
|
| Prospective Studies | 11 | 2023 | 1272 | 0.500 |
Why?
|
| Young Adult | 10 | 2023 | 2804 | 0.480 |
Why?
|
| Anxiety Disorders | 1 | 2016 | 65 | 0.480 |
Why?
|
| Carboxylesterase | 1 | 2015 | 1 | 0.470 |
Why?
|
| Fluorouracil | 6 | 2022 | 58 | 0.460 |
Why?
|
| Cancer Pain | 2 | 2025 | 16 | 0.460 |
Why?
|
| Immunotherapy | 5 | 2022 | 160 | 0.450 |
Why?
|
| Research Design | 1 | 2016 | 185 | 0.450 |
Why?
|
| Life Style | 1 | 2015 | 90 | 0.450 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2017 | 301 | 0.430 |
Why?
|
| Leucovorin | 5 | 2022 | 19 | 0.420 |
Why?
|
| Rectal Neoplasms | 2 | 2025 | 9 | 0.410 |
Why?
|
| Follow-Up Studies | 8 | 2019 | 1026 | 0.410 |
Why?
|
| Hospitals, Special | 1 | 2013 | 3 | 0.410 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 2013 | 10 | 0.410 |
Why?
|
| Chemoradiotherapy | 3 | 2024 | 44 | 0.400 |
Why?
|
| Chemokines | 1 | 2013 | 74 | 0.400 |
Why?
|
| Advance Care Planning | 2 | 2026 | 15 | 0.390 |
Why?
|
| Survival Rate | 9 | 2020 | 431 | 0.390 |
Why?
|
| Quality Assurance, Health Care | 1 | 2013 | 62 | 0.390 |
Why?
|
| Analgesics | 1 | 2012 | 38 | 0.380 |
Why?
|
| Veterans | 1 | 2013 | 69 | 0.380 |
Why?
|
| Aging | 2 | 2019 | 979 | 0.370 |
Why?
|
| Neoplasm Metastasis | 6 | 2020 | 164 | 0.370 |
Why?
|
| Neoplasm Staging | 5 | 2019 | 478 | 0.350 |
Why?
|
| Pain | 2 | 2015 | 258 | 0.350 |
Why?
|
| Cytokines | 1 | 2013 | 448 | 0.340 |
Why?
|
| Circulating Tumor DNA | 2 | 2021 | 2 | 0.340 |
Why?
|
| Antiemetics | 2 | 2020 | 4 | 0.340 |
Why?
|
| Insurance, Health | 4 | 2021 | 51 | 0.340 |
Why?
|
| Psychometrics | 4 | 2019 | 122 | 0.340 |
Why?
|
| Socioeconomic Factors | 4 | 2019 | 251 | 0.340 |
Why?
|
| Precision Medicine | 2 | 2021 | 76 | 0.330 |
Why?
|
| Massachusetts | 3 | 2019 | 17 | 0.330 |
Why?
|
| Ambulatory Care | 2 | 2021 | 60 | 0.330 |
Why?
|
| Stress, Psychological | 4 | 2021 | 229 | 0.320 |
Why?
|
| Goals | 2 | 2020 | 34 | 0.320 |
Why?
|
| Combined Modality Therapy | 3 | 2025 | 302 | 0.310 |
Why?
|
| Gastroenterologists | 2 | 2019 | 6 | 0.310 |
Why?
|
| End Stage Liver Disease | 2 | 2019 | 9 | 0.300 |
Why?
|
| Intensive Care Units | 2 | 2019 | 50 | 0.300 |
Why?
|
| Frailty | 2 | 2026 | 24 | 0.300 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2020 | 42 | 0.300 |
Why?
|
| Patient Care Planning | 2 | 2020 | 24 | 0.300 |
Why?
|
| Longitudinal Studies | 5 | 2026 | 426 | 0.290 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2018 | 194 | 0.290 |
Why?
|
| Patient Discharge | 2 | 2020 | 108 | 0.280 |
Why?
|
| Health Care Surveys | 2 | 2018 | 67 | 0.280 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2018 | 337 | 0.270 |
Why?
|
| Adolescent | 5 | 2023 | 3165 | 0.260 |
Why?
|
| Patient Outcome Assessment | 2 | 2019 | 14 | 0.260 |
Why?
|
| Cachexia | 2 | 2020 | 53 | 0.260 |
Why?
|
| Oncologists | 3 | 2021 | 15 | 0.250 |
Why?
|
| Family | 2 | 2017 | 98 | 0.250 |
Why?
|
| Biomarkers, Tumor | 3 | 2023 | 410 | 0.250 |
Why?
|
| Liver Neoplasms | 2 | 2020 | 167 | 0.250 |
Why?
|
| Mobile Applications | 1 | 2025 | 67 | 0.220 |
Why?
|
| Feasibility Studies | 2 | 2025 | 209 | 0.220 |
Why?
|
| Cost Savings | 1 | 2024 | 19 | 0.220 |
Why?
|
| Mass Screening | 2 | 2024 | 156 | 0.210 |
Why?
|
| Nausea | 2 | 2020 | 17 | 0.210 |
Why?
|
| Vomiting | 2 | 2020 | 14 | 0.210 |
Why?
|
| Biomedical Research | 1 | 2025 | 98 | 0.210 |
Why?
|
| Autoimmune Diseases | 1 | 2025 | 166 | 0.200 |
Why?
|
| Natural Language Processing | 1 | 2023 | 17 | 0.200 |
Why?
|
| Qualitative Research | 4 | 2025 | 200 | 0.190 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2023 | 28 | 0.190 |
Why?
|
| Coronary Vasospasm | 1 | 2022 | 4 | 0.190 |
Why?
|
| Prescriptions | 1 | 2022 | 3 | 0.190 |
Why?
|
| Mutation | 3 | 2021 | 864 | 0.180 |
Why?
|
| Logistic Models | 3 | 2020 | 409 | 0.180 |
Why?
|
| Cancer Care Facilities | 1 | 2021 | 9 | 0.180 |
Why?
|
| Lymphoma, Follicular | 1 | 2021 | 13 | 0.180 |
Why?
|
| Neoplasm, Residual | 1 | 2021 | 31 | 0.180 |
Why?
|
| Patient Satisfaction | 1 | 2022 | 96 | 0.180 |
Why?
|
| Mental Health Services | 1 | 2021 | 20 | 0.170 |
Why?
|
| Videoconferencing | 1 | 2021 | 10 | 0.170 |
Why?
|
| Telephone | 1 | 2021 | 26 | 0.170 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2021 | 44 | 0.170 |
Why?
|
| Gastroenterology | 1 | 2021 | 15 | 0.170 |
Why?
|
| Research | 1 | 2021 | 93 | 0.170 |
Why?
|
| Siblings | 2 | 2018 | 23 | 0.170 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2024 | 671 | 0.170 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2021 | 478 | 0.170 |
Why?
|
| Fellowships and Scholarships | 1 | 2021 | 40 | 0.170 |
Why?
|
| Poverty | 2 | 2024 | 89 | 0.170 |
Why?
|
| Neoplasms, Second Primary | 1 | 2020 | 21 | 0.170 |
Why?
|
| Weight Loss | 1 | 2021 | 83 | 0.170 |
Why?
|
| Electronic Health Records | 3 | 2026 | 63 | 0.160 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2022 | 164 | 0.160 |
Why?
|
| Fatigue | 3 | 2020 | 64 | 0.160 |
Why?
|
| Child | 4 | 2021 | 2271 | 0.160 |
Why?
|
| Anus Neoplasms | 1 | 2020 | 5 | 0.160 |
Why?
|
| Frail Elderly | 2 | 2026 | 16 | 0.160 |
Why?
|
| Indians, North American | 1 | 2024 | 534 | 0.160 |
Why?
|
| Veterans Health | 1 | 2019 | 6 | 0.160 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2019 | 4 | 0.160 |
Why?
|
| Liquid Biopsy | 1 | 2019 | 9 | 0.160 |
Why?
|
| DNA, Neoplasm | 1 | 2019 | 34 | 0.160 |
Why?
|
| Losartan | 1 | 2019 | 4 | 0.160 |
Why?
|
| Guideline Adherence | 1 | 2020 | 95 | 0.160 |
Why?
|
| Nursing Homes | 1 | 2019 | 50 | 0.150 |
Why?
|
| Public Health Surveillance | 1 | 2019 | 6 | 0.150 |
Why?
|
| Sexual Behavior | 1 | 2020 | 91 | 0.150 |
Why?
|
| Pandemics | 1 | 2021 | 196 | 0.150 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2020 | 117 | 0.150 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2020 | 133 | 0.150 |
Why?
|
| Carcinoma, Large Cell | 1 | 2018 | 6 | 0.150 |
Why?
|
| Atrial Fibrillation | 1 | 2023 | 402 | 0.150 |
Why?
|
| Quality of Health Care | 2 | 2021 | 83 | 0.150 |
Why?
|
| Attitude | 1 | 2019 | 44 | 0.150 |
Why?
|
| Decision Support Techniques | 1 | 2018 | 50 | 0.150 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2018 | 13 | 0.150 |
Why?
|
| Prescription Fees | 1 | 2018 | 3 | 0.140 |
Why?
|
| Liver Transplantation | 1 | 2019 | 56 | 0.140 |
Why?
|
| Psychological Tests | 1 | 2018 | 21 | 0.140 |
Why?
|
| Adipose Tissue | 1 | 2020 | 186 | 0.140 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2020 | 147 | 0.140 |
Why?
|
| Costs and Cost Analysis | 1 | 2018 | 40 | 0.140 |
Why?
|
| Program Evaluation | 1 | 2019 | 172 | 0.140 |
Why?
|
| Tumor Burden | 1 | 2018 | 110 | 0.140 |
Why?
|
| Health Services Needs and Demand | 1 | 2018 | 37 | 0.140 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2018 | 15 | 0.140 |
Why?
|
| Managed Care Programs | 1 | 2018 | 16 | 0.140 |
Why?
|
| Anorexia | 2 | 2015 | 4 | 0.140 |
Why?
|
| Time-to-Treatment | 1 | 2018 | 29 | 0.140 |
Why?
|
| Terminally Ill | 1 | 2017 | 2 | 0.140 |
Why?
|
| Employment | 1 | 2018 | 49 | 0.140 |
Why?
|
| Blood Vessels | 1 | 2018 | 58 | 0.140 |
Why?
|
| Resuscitation Orders | 1 | 2017 | 9 | 0.140 |
Why?
|
| Attitude to Death | 1 | 2017 | 13 | 0.140 |
Why?
|
| Pain Measurement | 3 | 2025 | 172 | 0.140 |
Why?
|
| Professional-Patient Relations | 1 | 2017 | 28 | 0.140 |
Why?
|
| Regression Analysis | 1 | 2018 | 210 | 0.130 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2017 | 42 | 0.130 |
Why?
|
| Health Surveys | 1 | 2017 | 84 | 0.130 |
Why?
|
| Endocrine Gland Neoplasms | 1 | 2017 | 2 | 0.130 |
Why?
|
| Aromatase Inhibitors | 1 | 2017 | 2 | 0.130 |
Why?
|
| Postoperative Complications | 1 | 2022 | 631 | 0.130 |
Why?
|
| Financial Support | 1 | 2016 | 9 | 0.130 |
Why?
|
| Molecular Targeted Therapy | 1 | 2018 | 137 | 0.130 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2017 | 98 | 0.130 |
Why?
|
| Interpersonal Relations | 1 | 2017 | 65 | 0.130 |
Why?
|
| Hospital Mortality | 1 | 2017 | 157 | 0.130 |
Why?
|
| Guidelines as Topic | 1 | 2016 | 46 | 0.130 |
Why?
|
| Glioma | 1 | 2018 | 121 | 0.130 |
Why?
|
| Health Status | 1 | 2017 | 148 | 0.120 |
Why?
|
| Physicians | 1 | 2016 | 83 | 0.120 |
Why?
|
| Forecasting | 1 | 2016 | 76 | 0.120 |
Why?
|
| Melanoma | 1 | 2017 | 140 | 0.120 |
Why?
|
| Brazil | 2 | 2025 | 24 | 0.120 |
Why?
|
| African Americans | 1 | 2018 | 352 | 0.120 |
Why?
|
| Delphi Technique | 1 | 2015 | 23 | 0.120 |
Why?
|
| Evidence-Based Medicine | 1 | 2016 | 146 | 0.120 |
Why?
|
| Social Support | 1 | 2016 | 128 | 0.110 |
Why?
|
| Organoplatinum Compounds | 1 | 2015 | 24 | 0.110 |
Why?
|
| Emotions | 1 | 2016 | 137 | 0.110 |
Why?
|
| Sex Characteristics | 1 | 2015 | 172 | 0.110 |
Why?
|
| Colonic Neoplasms | 1 | 2016 | 121 | 0.110 |
Why?
|
| Bevacizumab | 1 | 2015 | 106 | 0.110 |
Why?
|
| Cohort Studies | 3 | 2023 | 893 | 0.100 |
Why?
|
| Body Weight | 1 | 2014 | 250 | 0.100 |
Why?
|
| Prostatic Neoplasms | 1 | 2017 | 282 | 0.100 |
Why?
|
| Quality Indicators, Health Care | 1 | 2013 | 52 | 0.100 |
Why?
|
| Lymphatic Metastasis | 3 | 2018 | 126 | 0.100 |
Why?
|
| Consultants | 1 | 2012 | 4 | 0.100 |
Why?
|
| Data Collection | 1 | 2013 | 105 | 0.100 |
Why?
|
| Quality Improvement | 1 | 2013 | 123 | 0.090 |
Why?
|
| Time Factors | 3 | 2020 | 1600 | 0.090 |
Why?
|
| Gene Expression | 1 | 2013 | 417 | 0.090 |
Why?
|
| Cognition Disorders | 1 | 2013 | 186 | 0.090 |
Why?
|
| Glucose Intolerance | 1 | 2011 | 24 | 0.090 |
Why?
|
| Magnesium | 1 | 2011 | 42 | 0.090 |
Why?
|
| Comorbidity | 2 | 2023 | 259 | 0.080 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2021 | 33 | 0.080 |
Why?
|
| Polycystic Ovary Syndrome | 1 | 2011 | 65 | 0.080 |
Why?
|
| Postural Balance | 1 | 2009 | 41 | 0.080 |
Why?
|
| Insulin Resistance | 1 | 2011 | 176 | 0.080 |
Why?
|
| Hospices | 2 | 2020 | 7 | 0.080 |
Why?
|
| Survivorship | 2 | 2021 | 16 | 0.080 |
Why?
|
| Exercise Test | 1 | 2009 | 249 | 0.070 |
Why?
|
| Walking | 1 | 2009 | 135 | 0.070 |
Why?
|
| Hypertension | 1 | 2011 | 309 | 0.070 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2018 | 39 | 0.070 |
Why?
|
| B7-H1 Antigen | 2 | 2018 | 38 | 0.070 |
Why?
|
| Karnofsky Performance Status | 2 | 2020 | 15 | 0.070 |
Why?
|
| Incidence | 2 | 2021 | 568 | 0.070 |
Why?
|
| Neoplasm Invasiveness | 2 | 2018 | 190 | 0.070 |
Why?
|
| Survival Analysis | 2 | 2020 | 288 | 0.060 |
Why?
|
| Documentation | 1 | 2026 | 27 | 0.060 |
Why?
|
| Awareness | 1 | 2025 | 17 | 0.060 |
Why?
|
| Body Mass Index | 2 | 2021 | 405 | 0.060 |
Why?
|
| Charities | 1 | 2025 | 1 | 0.060 |
Why?
|
| Obesity | 1 | 2011 | 675 | 0.060 |
Why?
|
| Patient Care Team | 1 | 2024 | 66 | 0.050 |
Why?
|
| Child, Preschool | 2 | 2018 | 1167 | 0.050 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2023 | 3 | 0.050 |
Why?
|
| Bendamustine Hydrochloride | 1 | 2023 | 2 | 0.050 |
Why?
|
| Bone Marrow Transplantation | 1 | 2023 | 49 | 0.050 |
Why?
|
| Rituximab | 1 | 2023 | 64 | 0.050 |
Why?
|
| Minority Groups | 1 | 2023 | 75 | 0.050 |
Why?
|
| Calcium Channel Blockers | 1 | 2022 | 41 | 0.050 |
Why?
|
| Nitrates | 1 | 2022 | 51 | 0.050 |
Why?
|
| Drug Costs | 1 | 2021 | 17 | 0.050 |
Why?
|
| Microsatellite Repeats | 1 | 2021 | 59 | 0.050 |
Why?
|
| Drugs, Generic | 1 | 2021 | 6 | 0.050 |
Why?
|
| Radiotherapy | 1 | 2021 | 41 | 0.040 |
Why?
|
| Pharmacies | 1 | 2021 | 19 | 0.040 |
Why?
|
| Hematologic Tests | 1 | 2021 | 7 | 0.040 |
Why?
|
| Biological Specimen Banks | 1 | 2021 | 10 | 0.040 |
Why?
|
| Immunologic Factors | 1 | 2021 | 50 | 0.040 |
Why?
|
| Oncology Service, Hospital | 1 | 2020 | 1 | 0.040 |
Why?
|
| New England | 1 | 2020 | 8 | 0.040 |
Why?
|
| alpha-Fetoproteins | 1 | 2020 | 18 | 0.040 |
Why?
|
| Hospital Costs | 1 | 2020 | 30 | 0.040 |
Why?
|
| Hospitals | 1 | 2021 | 77 | 0.040 |
Why?
|
| Transportation of Patients | 1 | 2020 | 29 | 0.040 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2020 | 6 | 0.040 |
Why?
|
| Pneumonia, Aspiration | 1 | 2019 | 4 | 0.040 |
Why?
|
| Dehydration | 1 | 2019 | 7 | 0.040 |
Why?
|
| Renal Insufficiency | 1 | 2019 | 20 | 0.040 |
Why?
|
| Health Planning Guidelines | 1 | 2019 | 6 | 0.040 |
Why?
|
| Perception | 1 | 2020 | 90 | 0.040 |
Why?
|
| Whole Exome Sequencing | 1 | 2019 | 9 | 0.040 |
Why?
|
| Radiation Injuries | 1 | 2020 | 52 | 0.040 |
Why?
|
| Autopsy | 1 | 2019 | 26 | 0.040 |
Why?
|
| Genetic Heterogeneity | 1 | 2019 | 31 | 0.040 |
Why?
|
| Urinary Tract Infections | 1 | 2019 | 39 | 0.040 |
Why?
|
| Intersectoral Collaboration | 1 | 2019 | 7 | 0.040 |
Why?
|
| Waiting Lists | 1 | 2019 | 10 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2019 | 236 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2020 | 265 | 0.040 |
Why?
|
| Cultural Competency | 1 | 2019 | 18 | 0.040 |
Why?
|
| Pneumonia | 1 | 2019 | 89 | 0.040 |
Why?
|
| Sepsis | 1 | 2019 | 86 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2019 | 98 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2018 | 226 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2019 | 170 | 0.040 |
Why?
|
| Disease Progression | 1 | 2020 | 475 | 0.030 |
Why?
|
| Antacids | 1 | 2017 | 6 | 0.030 |
Why?
|
| Enzyme Replacement Therapy | 1 | 2017 | 4 | 0.030 |
Why?
|
| Models, Statistical | 1 | 2018 | 128 | 0.030 |
Why?
|
| Pancreatic Diseases | 1 | 2017 | 13 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2019 | 149 | 0.030 |
Why?
|
| Cause of Death | 1 | 2017 | 73 | 0.030 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2017 | 28 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2017 | 56 | 0.030 |
Why?
|
| Tamoxifen | 1 | 2017 | 33 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 236 | 0.030 |
Why?
|
| Family Health | 1 | 2016 | 71 | 0.030 |
Why?
|
| Linear Models | 1 | 2016 | 202 | 0.030 |
Why?
|
| Mental Health | 1 | 2016 | 110 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2017 | 333 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2017 | 622 | 0.030 |
Why?
|
| Dyspnea | 1 | 2015 | 25 | 0.030 |
Why?
|
| Constipation | 1 | 2015 | 22 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2018 | 899 | 0.030 |
Why?
|
| Internationality | 1 | 2014 | 31 | 0.030 |
Why?
|
| Syndrome | 1 | 2014 | 79 | 0.030 |
Why?
|
| Infant | 1 | 2018 | 1019 | 0.030 |
Why?
|
| Consensus | 1 | 2014 | 75 | 0.030 |
Why?
|
| Risk Factors | 1 | 2020 | 2111 | 0.030 |
Why?
|
| Terminology as Topic | 1 | 2014 | 61 | 0.030 |
Why?
|
| Prevalence | 1 | 2015 | 510 | 0.030 |
Why?
|
| Waist Circumference | 1 | 2011 | 20 | 0.020 |
Why?
|
| Body Weights and Measures | 1 | 2009 | 18 | 0.020 |
Why?
|
| Hand Strength | 1 | 2009 | 38 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2011 | 355 | 0.020 |
Why?
|
| Accidental Falls | 1 | 2009 | 32 | 0.020 |
Why?
|
| Lipids | 1 | 2011 | 214 | 0.020 |
Why?
|
| Gait | 1 | 2009 | 61 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2011 | 310 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2009 | 391 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2009 | 273 | 0.020 |
Why?
|
| Heart Rate | 1 | 2009 | 380 | 0.020 |
Why?
|
| Biomarkers | 1 | 2011 | 770 | 0.020 |
Why?
|